PR
RYTM icon

PSP Research’s Rhythm Pharmaceuticals RYTM Stock Holding History

PSP Research’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
+2,000
New +$181K 0.12% 65
2026
Q1 		– Sell
-4,738
Closed -$507K – 97
2025
Q4 		$507K Buy
+4,738
New +$503K 0.44% 72

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PSP Research's RYTM Position: Q2 2026 in Review

PSP Research opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 2,000 shares worth $222K. The stake represents 0.12% of the portfolio and ranks #65 among its holdings. This is a return to the name: PSP Research previously reported a position in RYTM as recently as Q4 2025.

PSP Research first reported a position in RYTM in Q4 2025 and has held it in 2 quarters since. The position peaked at $507K in Q4 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • PSP Research held 2,000 shares of Rhythm Pharmaceuticals worth $222K as of Q2 2026.
  • Rhythm Pharmaceuticals was a new PSP Research position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.12% of PSP Research's portfolio in Q2 2026, its #65 holding.
  • PSP Research first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • PSP Research's Rhythm Pharmaceuticals position peaked at $507K in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.